Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.

IF 1.8 Q3 PHARMACOLOGY & PHARMACY
Pharmaceutical patent analyst Pub Date : 2021-05-01 Epub Date: 2021-06-11 DOI:10.4155/ppa-2021-0002
Benjamin Brennecke, Thais Gazzi, Kenneth Atz, Jürgen Fingerle, Pascal Kuner, Torsten Schindler, Guy de Weck, Marc Nazaré, Uwe Grether
{"title":"Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.","authors":"Benjamin Brennecke,&nbsp;Thais Gazzi,&nbsp;Kenneth Atz,&nbsp;Jürgen Fingerle,&nbsp;Pascal Kuner,&nbsp;Torsten Schindler,&nbsp;Guy de Weck,&nbsp;Marc Nazaré,&nbsp;Uwe Grether","doi":"10.4155/ppa-2021-0002","DOIUrl":null,"url":null,"abstract":"<p><p>The G-protein-coupled cannabinoid receptor type 2 (CB<sub>2</sub>R) is a key element of the endocannabinoid (EC) system. EC/CB<sub>2</sub>R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB<sub>2</sub>R agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders. Existing ligands can be subdivided into endocannabinoids, cannabinoid-like and synthetic CB<sub>2</sub>R ligands that possess various degrees of potency on and selectivity against the cannabinoid receptor type 1. This review is an account of granted CB<sub>2</sub>R ligand patents from 2010 up to the present, which were surveyed using Derwent Innovation<sup>®</sup>.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical patent analyst","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/ppa-2021-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 9

Abstract

The G-protein-coupled cannabinoid receptor type 2 (CB2R) is a key element of the endocannabinoid (EC) system. EC/CB2R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB2R agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders. Existing ligands can be subdivided into endocannabinoids, cannabinoid-like and synthetic CB2R ligands that possess various degrees of potency on and selectivity against the cannabinoid receptor type 1. This review is an account of granted CB2R ligand patents from 2010 up to the present, which were surveyed using Derwent Innovation®.

大麻素受体2型配体:2010年以来授权专利分析。
g蛋白偶联大麻素受体2型(CB2R)是内源性大麻素(EC)系统的关键元件。EC/CB2R信号在过敏、神经退行性疾病、炎症或眼部疾病等影响人类的主要病理中具有重要的治疗潜力。CB2R激动剂在心血管、胃肠、肝、肾、肺和神经退行性疾病的临床前动物模型中具有抗炎和组织保护作用。现有的配体可细分为内源性大麻素(endocannabinoids)、类大麻素(cannabinoids -样大麻素)和合成CB2R配体,对大麻素受体1型具有不同程度的效力和选择性。本文回顾了2010年至今CB2R配体的授权专利,这些专利使用Derwent Innovation®进行了调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical patent analyst
Pharmaceutical patent analyst PHARMACOLOGY & PHARMACY-
CiteScore
1.80
自引率
0.00%
发文量
22
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信